Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

CAS No. :	1009820-21-6
Formula :	C₁₉H₁₂ClN₃O₂
M.W :	349.77
SMILES Code :	O=C(C1=CC=C2C(N=C(NC3=CC=CC(Cl)=C3)C4=C2C=NC=C4)=C1)O
Synonyms :	CX-4945
MDL No. :	MFCD13184796
InChI Key :	MUOKSQABCJCOPU-UHFFFAOYSA-N
Pubchem ID :	24748573

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H332-H335
Precautionary Statements:	P261-P280-P305+P351+P338

U87MG	25 μM	6 h	To study the effect of CK2 inhibitor on ECE1c stability, results showed that ECE1cK6R exhibited enhanced stability both in the presence and absence of silmitasertib.	PMC9914402
T98G	25 μM	6 h	To study the effect of CK2 inhibitor on ECE1c stability, results showed that ECE1cK6R exhibited enhanced stability both in the presence and absence of silmitasertib.	PMC9914402
U251	25 μM	6 h	To study the effect of CK2 inhibitor on ECE1c stability, results showed that ECE1cK6R exhibited enhanced stability both in the presence and absence of silmitasertib.	PMC9914402
MCF-7	1 μM	24 h	To evaluate the effect of Silmitasertib on cell viability. Results showed a significant reduction in cell viability.	PMC6530875
HCT-116	2 μM	48 h	To assess the impact of Silmitasertib on apoptosis. Results indicated an increase in apoptotic cells.	PMC6530875
H1299 cells	37 μM	1 h	To investigate the effect of Silmitasertib on N protein LLPS, results showed that Silmitasertib had no detectable effect on N protein LLPS.	PMC8035206
HNSCC cells (OSC19, UMSCC1, MDA1586)	0.5-10 µM	12-24 h	To evaluate the effect of Silmitasertib on HNSCC cell invasion, results showed that Silmitasertib significantly reduced extracellular matrix (ECM) degradation and invadopodia formation.	PMC6445698
PDX cells (WVUSCC-AR2, WVUSCC-AR5)	0.5-10 µM	24 h	To evaluate the effect of Silmitasertib on PDX cell invasion, results showed that Silmitasertib significantly reduced extracellular matrix (ECM) degradation and invadopodia formation.	PMC6445698
Cal-27	10, 20, 40 µM	24, 48 h	To test the effect of Silmitasertib combined with DDP treatment on the viability of Cal-27 cells, the results showed that the combined treatment significantly reduced cell viability.	PMC8592591
UM1	10, 20, 40 µM	24, 48 h	To test the effect of Silmitasertib combined with DDP treatment on the viability of UM1 cells, the results showed that the combined treatment significantly reduced cell viability.	PMC8592591
HSC-3	10, 20, 40 µM	12 h	To observe the effect of Silmitasertib on macropinocytosis in HSC-3 cells, the results showed that Silmitasertib induced cell vacuolation.	PMC8592591
HSC-4	10, 20, 40 µM	12 h	To observe the effect of Silmitasertib on macropinocytosis in HSC-4 cells, the results showed that Silmitasertib induced cell vacuolation.	PMC8592591

BALB/c nude mice	ovarian cancer xenograft model	oral	60 mg/kg	twice daily, until the end of the experiment	Silmitasertib significantly inhibited tumor growth	PMC11743126
Mice	Xenograft model	Oral	50 mg/kg	Once daily for 21 days	To determine the efficacy of Silmitasertib in reducing tumor growth. Results showed a significant reduction in tumor volume.	PMC6530875
Mice	HNSCC orthotopic tongue tumor model	Oral	50 mg/kg	Twice daily for three weeks	To evaluate the effect of Silmitasertib on HNSCC orthotopic tongue tumor invasion, results showed that Silmitasertib significantly reduced tumor invasion and perineural invasion.	PMC6445698
Nude mice	Cal-27 xenograft model	Peritumoral injection	60 mg/kg	Once every 5 days for 4 weeks	To verify the tumor suppressive effect of Silmitasertib combined with DDP in vivo, the results showed that the combined treatment significantly inhibited tumor growth.	PMC8592591

{[proInfo.proName]}

CAS No.: 1009820-21-6

{[proInfo.proName]}

CAS No.: 1009820-21-6

Product Citations

Alternative Products

Product Details of Silmitasertib

Safety of Silmitasertib

Related Pathways of Silmitasertib

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

NCT00891280	Advanced Solid Tumors ... More >> Breast Cancer Inflammatory Breast Cancer Castleman's Disease Multiple Myeloma Less <<	Phase 1	Unknown	December 2011	United States, Arizona ... More >> Mayo Clinic Arizona Recruiting Scottsdale, Arizona, United States, 85259 Contact: Clinical Trials Office Mayo Clinic Cancer Center 507-538-7623 Principal Investigator: Donald Northfelt, MD United States, Colorado Front Range Cancer Specialists Recruiting Fort Collins, Colorado, United States, 80528 Contact: P. Zeller 970-212-7609 Principal Investigator: Robert F Marschke, MD Front Range Cancer Specialists Recruiting Loveland, Colorado, United States, 80528 Contact: Pat Zeller 970-212-7609 Principal Investigator: R. McFarland, MD United States, Texas U T M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: R. Alvarez, MD ralvarez@mdanderson.org Principal Investigator: R. Alvarez, MD Less <<
NCT03571438	Kidney Cancer	Not Applicable	Recruiting	September 30, 2024	France ... More >> Grenoble Alps Hospital Recruiting Grenoble, France, 38043 Contact: Jean-Luc Descotes, PU-PH Less <<
NCT02128282	Cholangiocarcinoma	Phase 1 Phase 2	Recruiting	November 2021	United States, Arizona ... More >> Mayo Clinic Recruiting Scottsdale, Arizona, United States, 85259-5499 Contact: Mayo Clinic Clinical Trials Office 855-776-0015 Principal Investigator: Mitesh Borad, M.D. United States, Colorado University of Colorado- Denver Recruiting Aurora, Colorado, United States, 80045 Contact: Amy Szilard 720-848-0702 Amy.Szilard@ucdenver.edu Principal Investigator: Sarah (Lindsey) Davis, MD United States, Florida Mayo Clinic Recruiting Jacksonville, Florida, United States, 32224 Contact: Mayo Clinic Clinical Trials Office 855-776-0015 Principal Investigator: Kabir Mody, MD United States, Minnesota Mayo Clinic Recruiting Rochester, Minnesota, United States, 55905 Contact: Mayo Clinic Clinical Trials Office 855-776-0015 Principal Investigator: Joleen Hubbard, MD United States, Texas Texas Oncology - Baylor Charles A. Sammons Cancer Center Recruiting Dallas, Texas, United States, 75246 Contact: Tammy Carmical, RN 214-370-1937 tammy.carmical@usoncology.com Principal Investigator: Carlos Becerra, M.D. Texas Oncology-Tyler Recruiting Tyler, Texas, United States, 75702 Contact: Karen Poe, RN 903-579-9869 karen.poe@usoncology.com Principal Investigator: Donald A Richards, M.D. Korea, Republic of Asan Medical Center Recruiting Seoul, Songpa-gu, Korea, Republic of, 138-736 Contact: Heung-Moon Chang, MD 82-3010-3219 ext 3210 changhm@amc.seoul.kr Contact: Seok kyung Jeong 82-2-3010-5634 jsk0213@amc.seoul.kr Samsung Medical Center Recruiting Seoul, Korea, Republic of Contact: Eunyou Lee 82-2-3410-0955 ley0709@samsung.com Principal Investigator: Joon Oh Park, MD Seoul National University Hospital Recruiting Seoul, Korea, Republic of Contact: Myoungsun Choi 82-2-2072-7612 iamyou3@hanmail.net Principal Investigator: Do-Youn Oh, MD Severance Hospital, Yonsei University Health System Recruiting Seoul, Korea, Republic of Contact: So Young Hwang 82-2-2228-8180 syhwang@yuhs.ac Principal Investigator: Sun Young Rha, MD Taiwan China Medical University Hospital Recruiting Taichung City, Taiwan Contact: Pei-Chen Hsu +886-4-2205-2121 peggyshiu0807@gmail.com Principal Investigator: Li-Yuan Bai, M.D. Less <<
NCT01199718	Multiple Myeloma	PHASE1	UNKNOWN	2025-09-11	Kettering, Ohio, 45249, United... More >> States\|Oregon Health Science University, Portland, Oregon, 97239, United States\|Springfield, Oregon, 97477, United States\|Greenville, South Carolina, 29605, United States\|Norfolk, Virginia, 23502, United States\|Yakima, Washington, 98902, United States Less <<
NCT04668209	Coronavirus	PHASE2	TERMINATED	2022-10-19	Banner University Medical Cent... More >>er Phoenix, Phoenix, Arizona, 85006, United States\|Banner University Medical Center Tucson, Tucson, Arizona, 85724, United States Less <<
NCT05817708	COVID-19	PHASE1	COMPLETED	2023-06-20	Taipei Medical University Hosp... More >>ital, Taipei, 110301, Taiwan Less <<
NCT03897036	Carcinoma, Basal Cell	PHASE1	ACTIVE_NOT_RECRUITING	2025-12-23	University of Colorado Anschut... More >>z Medical Campus, Aurora, Colorado, 80045, United States\|H. Lee Moffitt Cancer Center & Research Institute, Inc., Tampa, Florida, 33612, United States\|University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States\|Inova Schar Cancer Institute, Fairfax, Virginia, 22031, United States Less <<

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed